Stock code: 002653.SZ
Beichangping® (Cofrogliptin Tablets)
Officially approved in June 2024, it is theworld's first biweekly ultra-long-acting oral hypoglycemic agent, achieving innovative first launch in China. With only 26 doses required per year, it improves patient compliance, enables long-term stable glycemic control, offers high safety, and is not restricted by liver or kidney function, providing long-term benefits to patients and filling the gap in the field of long-acting oral hypoglycemic agents in China.
[1] Package Insert of Cofrogliptin Tablets.
[2] Bai N, et al. Diabetes Ther. January 2024;15(1):183-199.
[3] Pan C, J, et al. Diabetes Obes Metab. February 2026;28(2):1191-1200.
[4] Gao L, et al. Diabetes Obes Metab. January 2025;27(1):280-290.
[5] Ren Q, et al. Diabetes Obes Metab. November 2024;26(11):5013-5024.Aschner P, et al. Diabetes Care
[6] Aschner P, et al. Diabetes Care. 2006 Dec;29(12):2632-7.
[7] Dejager S, et al. Horm Metab Res. 2007 Mar;39(3):218-23.
[8] Rosenstock J, et al. Curr Med Res Opin. 2009 Oct;25(10):2401-11.
[9] Del Prato S, et al. Diabetes Obes Metab. 2011 Mar;13(3):258-67.
[10] DeFronzo RA, et al. Diabetes Care. 2008 Dec;31(12):2315-7.
Download prescribing information
12 papers in top journals, including Journal of Medicinal Chemistry, Diabetes Obesity & Metabolism, etc.;
Presentations at 8 Global Top-tier Conferences such as ADA (American Diabetes Association), EASD (European Association for the Study of Diabetes), and ENDO (The Endocrine Society), showcasing China's original hypoglycemic drug research achievements to the world;
Recommended by 7 authoritative guidelines and expert consensus, including Chinese Guideline for Diabetes Prevention and Treatment (2024 Edition) and National Guidelines for Prevention and Management of Diabetes in Primary Care (2025 Edition);
What is the global first-in-class status of Beichangping® (Cofrogliptin) in the field of hypoglycemic agents?
It is the world's first biweekly ultra-long-acting oral hypoglycemic agent, filling the gap in this field in China.
When was Beichangping® (Cofrogliptin) approved?
It was officially approved in June 2024.
What is the core indication of Beichangping® (Cofrogliptin)?
It is indicated to improve glycemic control in adults with type 2 diabetes mellitus.
What is the dosing cycle of Beichangping® (Cofrogliptin)?
It only needs to be taken once every two weeks.
How long is the half-life of Beichangping® (Cofrogliptin)?
The long half-life can reach up to 131.5 hours.
What is the enzyme inhibition effect of Beichangping® (Cofrogliptin) after administration?
A single oral dose maintains DPP-4 enzyme inhibition rate above 80% for two weeks.
Is Beichangping® (Cofrogliptin) suitable for patients with hepatic or renal insufficiency?
No dose adjustment is required for patients with renal insufficiency or mild hepatic insufficiency, offering safety and peace of mind.
Is the risk of hypoglycemia high with Beichangping® (Cofrogliptin)?
Due to its glucose-dependent glucose-lowering mechanism, the risk of hypoglycemia is extremely low.
How do the side effects and drug interactions of Beichangping® (Cofrogliptin) perform?
It has few side effects and few drug interactions.
As of May 2026, how many academic papers on Beichangping® (Cofrogliptin) have been published?
A total of 12 related academic papers have been published to date.
In which renowned journals have papers on Beichangping® (Cofrogliptin) been published?
They include Journal of Medicinal Chemistry and Diabetes Obesity & Metabolism, etc.
As of May 2026, how many times has Beichangping® (Cofrogliptin) been presented at global top-tier academic conferences?
It has been presented 8 times at global top-tier academic conferences.
At which international diabetes conferences has Beichangping® (Cofrogliptin) been presented?
They include ADA (American Diabetes Association), EASD (European Association for the Study of Diabetes), and ENDO (The Endocrine Society), etc.
What are the presentation forms for study results of Beichangping® (Cofrogliptin) at international conferences?
Study results are presented to the world in the form of oral presentations and posters.
As of May 2026, how many expert guidelines has Beichangping® (Cofrogliptin) been included in?
It has been formally included in 7 authoritative guidelines and expert consensus statements.
Which core diabetes mellitus guidelines has Beichangping® (Cofrogliptin) been included in?
They include Chinese Guideline for Diabetes Prevention and Treatment (2024 Edition) and National Guidelines for Prevention and Management of Diabetes in Primary Care (2025 Edition), etc.
What is the medical insurance access status of Beichangping® (Cofrogliptin)?
It underwent its first medical insurance negotiation in 2024 and was successfully included in the National Reimbursement Drug List in 2025.
As of May 2026, how many hospitals has Beichangping® (Cofrogliptin) entered?
It has been adopted and prescribed in 6,028 medical institutions nationwide.
As of May 2026, how many patients with diabetes mellitus have cumulatively benefited from Beichangping® (Cofrogliptin)?
It has cumulatively benefited 400,000+ patient visits.
What is the summary of the greatest advantages of Beichangping® (Cofrogliptin)?
It has three core advantages: ultra-long-lasting efficacy, hepatic or renal safety, and stable glycemic control.
